For the week, the worst sectors according to Portfolio Grader are the reit, water utilities, independent power and renewable electricity producers, metals and mining and energy services sectors.
Top 10 Gold Companies To Invest In Right Now: Maximus Inc (MMS)
MAXIMUS, Inc., incorporated on October 18, 2007, provides business process services (BPS) to government health and human services agencies under its mission of Helping Government Serve the People. The Company is primarily focused on operating government-sponsored programs, such as Medicaid, Children's Health Insurance Program (CHIP), health insurance exchanges and other health care reform initiatives, Medicare, welfare-to-work, child support services and other government programs.
The Company is one of the pure-play health and human services administrative providers to governments in the United States, Australia, Canada, the United Kingdom and Saudi Arabia. The Company�� segments include Health Services and Human Services. Effective July 1, 2013, MAXIMUS, Inc. acquired Health Management Ltd.
Health Services Segment
The Company's Health Services segment provides a variety of business process services, as well as related consulting services, for state, provincial and federal government programs, including Medicaid, CHIP, SNAP (Supplemental Nutrition Assistance Program), Medicare, the Affordable Care Act and Health Insurance BC (British Columbia). In this segment, the Company's BPS and consulting services include government health insurance program administration; Health insurance program eligibility and enrollment services to improve access to health care for citizens and help beneficiaries make the best choice for their health insurance coverage; Eligibility and enrollment modernization for government health benefit programs; Health insurance exchange design and operations; Consumer outreach and education, including multilingual customer contact centers and multi-channel self-service options, such as Web-based portals, for easy enrollment; Application assistance and independent enrollment counseling to beneficiaries; Premium payment processing and administration, such as invoicing and reconciliation; Objective, evidence-based health appeals; Independent medical! reviews; Health plan oversight; eHealth solutions with the Medigent product suite; Medicaid Management Information System (MMIS) planning and oversight, and Specialized program consulting services.
Human Services Segment
The Company's Human Services segment provides federal, national, state and county human services agencies with a variety of business process services, as well as related consulting services for welfare-to-work, child support, higher education and K-12 special education programs. The Company's services include welfare-to-work services, including eligibility determination, case management, job-readiness preparation, job search and employer outreach, job retention and career advancement, and selected educational and training services, to help disadvantaged individuals transition from government assistance programs to sustainable employment and economic independence; Full and specialized child support case management services, customer contact center operations, and program and systems consulting services; Management tools and professional consulting services for higher education institutions; K-12 special education case management solutions; Program consulting services, including independent verification and validation, cost allocation plans, repeatable management services and other specialized consulting offerings, and Tax credit and employer services.
The Company competes with Serco, Atos Origin and Ingeus.
Advisors' Opinion:- [By Dan Caplinger]
Dow 16,000, S&P 1,800, and Nasdaq 4,000 didn't become reality today, but each of these benchmarks came close to reaching those respective levels as investors continued to respond favorably to the macroeconomic and monetary-policy environment going forward. But despite the market's broad gains, Electronic Arts (NASDAQ: EA ) , Maximus (NYSE: MMS ) , and Western Union (NYSE: WU ) gave up ground today with fairly substantial drops. Let's take a closer look at why these stocks bucked the market's favorable trend today.
Top 5 Managed Healthcare Stocks To Invest In 2014: WisdomTree Europe SmallCap Dividend Fund (DFE)
WisdomTree Europe SmallCap Dividend Fund is a non-diversified fund. It seeks investment results that closely correspond to the price and yield performance, before fees and expenses, of the WisdomTree Europe SmallCap Dividend Index.
The WisdomTree Europe SmallCap Dividend Index is a fundamentally weighted index that measures the performance of the small-capitalization segment of the European dividend-paying market. The Index is comprised of the companies that compose the bottom 25% of the market capitalization of the WisdomTree Europe Dividend Index.
Advisors' Opinion:- [By Matthew McCall]
The European equity rebound continues and within the region the small cap stocks have been quietly performing very well. The WisdomTree Europe Small Cap Dividend ETF (NYSE: DFE) focuses on small cap stocks that pay high dividends.
Top 5 Managed Healthcare Stocks To Invest In 2014: Industrias CH SAB de CV (ICHB)
Industrias CH SAB de CV (ICH) is a Mexico-based holding company engaged, together with its subsidiaries, in the steel industry. The Company's activities include the production, processing and distribution of special bar quality (SBQ) steel products; coated and uncoated seamed pipes; structural steel products, such as beams, channels, flat bars and angles; light structurals, such as angles, flat and merchant bars; as well as reinforced and corrugated steel bars. The Company�� facilities include production and processing plants in Mexico, the United States and Canada. Advisors' Opinion:- [By Julia Leite]
The IPC rose 2.5 percent to 40,623.30 at the close in Mexico City. The index gained 6.8 percent on the week, the most since July 2009. Steelmaker Industrias CH SAB (ICHB) was the biggest gainer today, while homebuilders Desarrolladora Homex SAB, Urbi Desarrollos Urbanos SAB, and Corp. Geo SAB were the week�� best performers.
Top 5 Managed Healthcare Stocks To Invest In 2014: Cancer Genetics Inc (CGIX)
Cancer Genetics, Inc. (CGI), incorporated on April 8, 1999, is an early-stage, diagnostic company. The Company focuses on developing and commercializing genomic tests and services to improve the diagnosis, prognosis and response to treatment (theranosis) of cancer. These cancers include hematological, urogenital and human papillomavirus (HPV)-associated cancers. It provides its tests and services to oncologists and pathologists at hospitals, cancer centers, and physician offices. In January 2012, the Company received CLIA approval for MatBA-SLL, its microarray for risk stratification in small lymphocytic lymphoma (SLL). In February 2013, the Company received CLIA approval for MatBA-DLBCL, its microarray for diagnosis, prognosis and patient monitoring in diffuse large B cell lymphoma (DLBCL). In addition, the Company is developing a series of other genomic tests in its core oncology markets. The Company develops and produces two types of deoxyribonucleic acid (DNA)-based genomic tests: microarrays and probes.
The Company is in the final stages of validating MatBATM-SLL for risk stratification in small lymphocytic lymphoma (SLL), a subset of CLL that presents as a mass, with Memorial Sloan-Kettering Cancer Center and Long Island Jewish / North Shore Hospital. The Company is also internally clinically validating the MatBATM microarray in a variety of additional lymphoma subtypes, including mantle-cell lymphoma (MCL), follicular lymphoma (FL), and diffuses large B cell lymphoma (DLBCL). Its MatBATM array has been designed to measure genetic markers at 80 specific genomic sites where genetic alterations are associated with mature B cell neoplasms.
CGI is also developing microarray tests for the diagnosis, prognosis and theranosis of a range of urogenital cancers. These include the UroGenRA microarray for kidney, prostate and bladder cancers and the UGenRA microarray for endometrial (lining of the uterus), ovarian and cervical cancers. UroGenRA detects genomic changes in over 100 r! egions of the human genome with potential diagnostic and/or prognostic value in one or more of these types of cancer. It has initiated clinical validation for UroGenRA targeting kidney and prostate cancers in collaboration with Memorial Sloan-Kettering Cancer Center. Its UGenRA microarray has been designed as a platform to detect genomic changes occurring in 83 regions of the human genome that have been linked to endometrial, ovarian and cervical cancers In addition, it develop and manufacture a portfolio of fluorescence in situ hybridization (FISH) based DNA probes focused on blood-based and solid cancers that it sell outside the United States. The Company laboratory services include: Oncology Testing Services, which are based on its microarray tests and are available only in its clinical laboratory; Esoteric Oncology Testing Services, which it offers a suite of esoteric oncology testing services for hematological, urogenital and HPV-associated cancers, and Clinical Trial Services, which also utilize its clinical laboratory to provide clinical trial services to biopharmaceutical companies and clinical research organizations.
Hematological Cancer Arrays: MatBA-CLL/SLL, Other Mat-BA and LeukA
MatBA is an oligonucleotide-based microarray the Company developed for the analysis of genomic alterations in mature B-cell neoplasms to determine prognosis and theranosis. MatBA incorporates a common architecture of specific genomic regions that can be applied across the seven major mature B-cell neoplasms. As a group, hematologic cancers (cancers of the blood, bone marrow or lymph nodes) display clinical, pathologic and genetic complexity. Importantly, the clinical course of the six main subtypes of these neoplasms ranges from indolent (follicular lymphoma) to aggressive (diffuse large B-cell lymphoma, mantle cell lymphoma and multiple myeloma), or mixed (chronic lymphocytic leukemia/small lymphocytic lymphoma, or CLL/SLL).
MatBA is designed to detect genomic copy number chan! ges in ma! ture B-cell neoplasms. The test relies on the comparative genomic hybridization of fluorescently differentially-labeled normal DNA and DNA extracted from the cancer specimen (array-CGH). Array-CGH utilizes minimal biopsy material and uses DNA as the analyte (the component whose properties are being measured). MatBA was custom-designed to represent 80 regions of the human genome which have diagnostic and/or prognostic value in one or more of the mature B-cell neoplasm subtypes as identified through our research and analysis efforts. Unlike other technologies such as FISH, array-CGH using MatBA simultaneously permits the detection of genomic gains and losses at multiple locations on a chromosome (loci) that characterize the mature B-cell neoplasm subtypes. For each subtype of B-cell neoplasm, cohorts of specimens with full clinical annotation are evaluated using MatBA to identify associations between single and weighted combinations of genomic gains/losses and clinically relevant endpoints.
The Company offers the application of MatBA for prognostication in one subtype of mature B-cell neoplasm, CLL, where about half of patients experience indolent disease, or slow progression, and the remaining half, a relatively aggressive progression. MatBA-CLL provides genetic-based information to guide clinical management of this disease. In January 2012, MatBA-SLL was approved under CLIA and accordingly may now be offered as an LDT by its laboratory. In January 2013, this assay received approval by CLIA and New-York State for clinical use, and accordingly may now be offered as an LDT by our reference laboratory.
During the year ended December 31, 2012, the Company had similar development of MatBA as a prognostic tool in two of the other main subtypes of mature B-cell lymphomas, namely DLBCL and FL. FL is characterized by a slow progression that in up to approximately 60% of cases transforms to DLBCL, an aggressive lymphoma. Prognostic and theranostic biomarkers of therapeutic options are req! uired for! these diseases.
Urogenital cancer arrays: UroGenRA, UGenRA
The UroGenRA microarray provides diagnostic and prognostic analysis for kidney, bladder and prostate cancer. Its initial launch, UroGenRA-Kidney targets kidney cancer. It also develops extensions of UroGenRA for bladder and prostate cancers. UGenRA provide diagnostic, prognostic and theranostic information for the primary gynecological cancers, cervical, ovarian and endometrial. UroGenRA is a CGH-based array which serves as a platform for the diagnosis, prognosis and theranosis of kidney, prostate and bladder cancers. It represents 101 regions of the human genome potentially with diagnostic, prognostic and/or theranostic value in one or more of these types of cancers. UroGenRA-Kidney For kidney cancer, UroGenRA is specifically designed to classify renal tumors into the four main subtypes (clear cell, papillary, chromophobe and oncocytoma), which is critical to patient management and treatment protocols.
UroGenRA-Prostate for prostate cancer, UroGenRA use prostate core/needle biopsy to assess genomic variability of the cancer and help in the identification of biomarkers for assessment of the risk of recurrence, to assess treatment options for intermediate risk patients, and to explore the genomic aberrations of circulating tumor cells. UroGenRA-Prostate is in the commercial development stage. UroGenRA-Bladder is a diagnosed bladder cancers are defined by the fact or extent of invasion of the muscle. UroGenRA-Bladder is in the clinical development stage.
UGenRA for Endometrial, Ovarian and Cervical Cancers
UGenRA is designed as a platform to detect gains and losses of genomic material in 83 regions of the chromosome associated with responses to particular therapies in patients with endometrial, ovarian and cervical. UGenRA-Endometrial Endometrial cancer is common cancer in women in the United States. In this disease, endometrial hyperplasia is a precursor lesion of endometr! ioid endo! metrial carcinoma (EEC). UGenRA Endometrial is in the clinical development stage.
UGenRA-Ovarian is cases of ovarian cancer. UGenRA Ovarian is in the clinical development stage. As of December 31, 2012, UGenRA-Cervical was approximately 11,270 cases of cervical cancer diagnosed and approximately 4,290 deaths from cervical cancer in the United States. UGenRA Cervical is in the clinical development stage.
Advisors' Opinion:- [By RedChip]
Cancer Genetics (NASDAQ: CGIX), an emerging leader in DNA-based cancer diagnostics, priced a $15 million secondary offering and began trading on the NASDAQ today.
The offering will bring in a sizable cash infusion to CGIX, setting the stage for continued expansion of the Company�� sales and marketing efforts, as well as further product development and commercialization. In addition, it will enable the Company to fund its joint venture investment with Mayo Clinic and retire mezzanine financing. - [By RedChip]
In an amended S-1 filed with the SEC this morning, Cancer Genetics, Inc. (NASDAQ: CGIX) added two new firms to its offering syndicate and upped its capital raise 25% to $50 million. With the underwriters��overallotment, the total raise is now forecasted to reach as much as $57.5 million.
No comments:
Post a Comment